

2025 APRN CONFERENCE SESSIONS

Session #	Topic	Presenter	CE Hours	Pharm	CS	Outcome(s)
1	MS State Health Department Update	Daniel Edney, MD, FACP, FASAM	1.0			L/C
2	BON APRN Update Including Weight Loss Medications & Opioids	Rebecca Cagle, PhD, DNP, FNP-BC, PMHNP-BC, NEA-BC, DipACLM	1.0		0.5*	L/C/S/P
3	Cannabis Use Disorder: "Cannabis in Mississippi: Regulatory Update, Drug Interactions, and Cannabis Use Disorder (CUD)"	Robert Welch, PharmD	1.0		1*	C/P
4	Empowering NPs in Obesity Care: Updates on Prescribing Regulations and Pharmacology Review	Christy Davis, DNP, FNP-C	2.0	1.5	0.5*	C/P
5	Chronic Wound Infection, Antibiotic Stewardship, and The Ever-Elusive Biofilm	Tomekia Luckett, PhD, APRN, PMHNP-BC	1.0	0.5		L/C/S/P
6	The lived experiences of families of an adult community dwelling person who uses drugs: a qualitative systematic review	Candace Magan Evans, DNP, RN, CNE	1.0			L/S
7	Hematology in Primary Care: When to Treat & When to Refer	Phyllis Fiveash, DNP, FNP-BC	1.0	0.25		L/C/P
8	Adolescent Obesity: Solving Tomorrow's Problems Today	Marcia Garrett, MSN, RN, FNP-C	1.0	0.5		L/C/P
9	Expanding the Neuropharmacological Framework for Schizophrenia Treatment	Rod Green, MSN, PMHNP-BC	1.5	1.5		L/C/P
10	Osteoporosis: Understanding Management and Treatment Strategies	Alena Groves, DNP, FNP-C, ONP-C	1.0	1.0		L/C/P
11	Paws for Wellness: Exploring the Mental Health Benefits of Pet Therapy for Depression and Loneliness	Tasha Jones Nelson, DNP, MBA-C, A-GPCNP, PMHNP	1.0			L/C
12	The Nurse Practitioner as Health Coach: Transforming Primary Care through Leadership and Evidence-Based Wellness Strategies	Tamekia Lindsay, MSN, APRN, FNP-BC	1.0			L/S
13	Obstructive Sleep Apnea-Impact on Wellness	Lora Lonidier, DNP, ACNP-BC, FNP-BC, CCRN, FAPAPP	1.0	0.5		C/P
14	Sex, Drugs, and Rock-n-Roll: Geriatric Considerations for Benzodiazepine Prescribing	Tomekia Luckett, PhD, APRN, PMHNP-BC	1.0		1*	L/C/P
15	The Evolving Landscape of ADHD Treatment: 2025 Research Update	Carl Mangum, PhD, PMHNP-BC, NHDP-BC	1.25		1*	L/C/P
16	Clostridioides difficile (C. diff): Management and Treatment	Julie McCord, NP-C, MPH, CIC	1.25	0.75		C/P
17	Pediatric Eye Exam	Anne Norwood, PhD, FNP-BC	1.0	0.5		L/C/P
18	Breast Cancer Update: Stats, Screening, and Treatments	Christy Savell, PhD, AGPCNP-BC, FNP-BC, CNE	1.0	0.5		L/C/P
19	Playing Chess in a Checkers Game: Strategies for Effective Advocacy	Deloris Slade, DNP, FNP-BC	2.0			L
20	Poster Presentations	Various Presenters:	0.5			S
		Victoria Pleshkan, PhD, APRN, FNP-C				
		Phoebe Thriffiley, MPH, BSN, RN, NE-BC, CPHRM, CPHQ, CIC, LSSGBC				
		Reba Umberger, PhD, RN				
*Any controlled substance credits can be counted as pharmacology or controlled substance, but not both.			TOTAL HOURS	22.5	7.5	4.0

OUTCOMES FOR APRN SPRING CONFERENCE

Leadership/Scholarship (L)

- Attendees will report enhanced motivation to improve nursing leadership skills in the areas of patient care, nursing self-care, mentor-ship of novice nurses, and/or clinical scholarship.
- Attendees will express augmented motivation to participate in education of either healthcare recipients or education of fellow participants in the provision of healthcare (student, novice, or expert).

Clinical (C)

- Attendees will express a gain in new evidence-based knowledge for translation into clinical practice.
- Attendees will report a satisfactory review of standards of care for improvements in clinical practice.

Scholarship (S)

- Attendees will evaluate nursing research presentations for efficacy and translation to practice.
- Attendees will express confidence in results presented of nursing research with intent to use in practice.

Pharmacology (P)

- Attendees will report new or increased knowledge of specific medications included in controlled substance classes of medications, medication management of specific conditions, or prescribing parameters for new drugs, enabling improvement in prescriptive practices.